Safety and tolerability profile of INLYTA® (axitinib)

INLYTA® has a well-documented side-effect profile which is generally manageable2

Adapted from Rini BI, et al. 2011 and INLYTA Summary of Product Characteristics.

  • The most common (≥20%) adverse reactions observed with INLYTA® were diarrhoea, hypertension, fatigue, decreased appetite, nausea, dysphonia and palmar-plantar erythrodysaesthesia (hand-foot syndrome)2
  • Discontinuation due to treatment-related AEs occurred in 4% (14/359) of patients treated with INLYTA® compared with 8% (29/355) of patients treated with sorafenib2

Please see the INLYTA® Summary of Product Characteristics for full safety information

References
1. INLYTA® Summary of Product Characteristics.
2. Rini BI, et al. Lancet 2011;378(9807):1931–1939.

PP-INL-IRL-0060 April 2020